Bearish flow noted in Roivant Sciences with 3,918 puts trading, or 5x expected. Most active are Jan-24 10 puts and Aug-24 11 puts, with total volume in those strikes near 3,700 contracts. The Put/Call Ratio is 16.39, while ATM IV is up over 1 point on the day. Earnings are expected on February 12th.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ROIV:
- Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
- Roche completes acquisition of Telavant from Roivant
- Roivant Sciences initiated with bullish view at Deutsche Bank, here’s why
- Roivant notes Immunovant data from Phase 1 IMVT-1402 trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue